Summary
The subgroup of patients with the EGFR-activating mutation in exon 19 or 21 appeared to have a favorable trend for dacomitinib vs erlotinib in progression-free survival. Afatinib was favored over erlotinib for second-line treatment of advanced squamous cell carcinoma in terms of progression-free survival, overall response rate, and disease control rate.
- dacomitinib
- erlotinib
- afatinib
- tyrosine kinase inhibitor
- non–small cell lung cancer
- progression-free survival
- ARCHER 1009
- LUX-8 Lung
- drug therapy
- EGFR
- squamous cell carcinoma
- oncology clinical trials
- head & neck cancers
- © 2015 SAGE Publications
Tools
ARCHER 1009 Subset Analysis and LUX-8 Lung: Erlotinib Compared With Dacomitinib or Afatinib
Permalink:
Table of contents
Cited By...
- No citing articles found.